These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 28600333)
21. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Petrich AM; Nabhan C; Smith SM Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588 [TBL] [Abstract][Full Text] [Related]
22. Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation. Cambruzzi E World Neurosurg; 2020 Feb; 134():215-220. PubMed ID: 31605845 [TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234 [TBL] [Abstract][Full Text] [Related]
24. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071 [TBL] [Abstract][Full Text] [Related]
25. Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. Menguy S; Frison E; Prochazkova-Carlotti M; Dalle S; Dereure O; Boulinguez S; Dalac S; Machet L; Ram-Wolff C; Verneuil L; Gros A; Vergier B; Beylot-Barry M; Merlio JP; Pham-Ledard A Mod Pathol; 2018 Aug; 31(8):1332-1342. PubMed ID: 29581544 [TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma. Badri N; Ngamdu KS; Torabi A; Guar S J Cancer Res Ther; 2020; 16(1):183-185. PubMed ID: 32362635 [TBL] [Abstract][Full Text] [Related]
27. Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Brunn A; Nagel I; Montesinos-Rongen M; Klapper W; Vater I; Paulus W; Hans V; Blümcke I; Weis J; Siebert R; Deckert M Acta Neuropathol; 2013 Oct; 126(4):603-5. PubMed ID: 24061549 [No Abstract] [Full Text] [Related]
28. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data]. Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736 [TBL] [Abstract][Full Text] [Related]
29. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. Wang W; Hu S; Lu X; Young KH; Medeiros LJ Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391 [TBL] [Abstract][Full Text] [Related]
30. ID3 mutations are recurrent events in double-hit B-cell lymphomas. Gebauer N; Bernard V; Feller AC; Merz H Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112 [TBL] [Abstract][Full Text] [Related]
31. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently? Davies A Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):284-294. PubMed ID: 29222268 [TBL] [Abstract][Full Text] [Related]
32. Double hit and double expressors in lymphoma: Definition and treatment. Riedell PA; Smith SM Cancer; 2018 Dec; 124(24):4622-4632. PubMed ID: 30252929 [TBL] [Abstract][Full Text] [Related]
33. Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy. Tumati V; Trivedi L; Li HC; Patel P; Scaglioni PP; Vusirikala M; Sadeghi N; Rizvi S; Chen W; Wachsmann J; Collins R; Desai NB Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1126-1132. PubMed ID: 29722657 [TBL] [Abstract][Full Text] [Related]
34. Prognostic Significance of Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031 [TBL] [Abstract][Full Text] [Related]
35. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens. Kim H; Kim HJ; Kim SH Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849 [TBL] [Abstract][Full Text] [Related]
36. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas]. Gerhard-Hartmann E; Rosenwald A Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092 [TBL] [Abstract][Full Text] [Related]